Meet the people leading our vision and growth.
Bobby Sheng, Chairman of Bora Group and CEO of Bora Pharmaceuticals, founded Bora Pharmaceuticals in 2007 with the vision of building a world-class CDMO. Drawing on over 25 years of expertise in the biotech and healthcare industry, he has led Bora to become Taiwan’s top CDMO by manufacturing capacity, exporting products to more than 100 countries.
Under Bobby’s leadership, Bora leverages a unique dual-engine business model, combining CDMO capabilities with drug development and commercialization to streamline product development, accelerate time-to-market, and scale manufacturing for pharma and biotech partners worldwide. Through strategic acquisitions in Taiwan, Canada, and the U.S., he has positioned Bora as a global leader in both small- and large-molecule CDMO services.
Bobby’s dedication to innovation, quality, and community impact has earned him several accolades, including CEO of the Year at the CPHI Awards and recognition from Taiwan’s President. He holds a bachelor’s degree in economics from the University of California, Berkeley.
Honorary Professor at National Taiwan University and Chief R&D Officer of SunWay Biotech, brings over 30 years of expertise in functional microbiology and fermentation science. He led the development of proprietary strains—including Monascus purpureus NTU 568 and Lactobacillus paracasei NTU 101—now foundational to ANKASCINR 568 and VigiisR 101. Beyond these breakthroughs, he has guided SunWay’s R&D team in advancing microbial screening, precision fermentation, and the development of bioactive compounds to drive innovation in consumer health care.
Under his leadership, SunWay has transformed academic research into globally competitive health ingredients. With FDA NDI approval, over 200 scientific publications, and recognition as a 2012 IFT Fellow, Professor Pan continues to shape the future of biotech innovation through the power of microbial science.
